In March 2025, the company declared new plans for just a direct-to-purchaser offering of its Wegovy weight loss drug. The company established a different pharmacy, termed NovoCare, which might cost shoppers $499 each month for access to the drug, a lot less than 50 percent the expense of the drug through other pharmaceutical distribution networks.[